Showing 10,301 - 10,320 results of 18,134 for search 'significantly ((((larger decrease) OR (((nn decrease) OR (a decrease))))) OR (linear decrease))', query time: 0.49s Refine Results
  1. 10301

    Table 1_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.xlsx by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  2. 10302

    Image 2_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  3. 10303
  4. 10304

    Image 7_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  5. 10305

    Image 8_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  6. 10306

    Image 6_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  7. 10307

    Image 1_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  8. 10308

    Image 3_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  9. 10309

    Table 1_Characterizing HLA-A2-restricted CD8+ T-cell epitopes and immune responses to Omicron variants in SARS-CoV-2-inactivated vaccine recipients.doc by Chanchan Xiao (9522614)

    Published 2025
    “…</p>Methods<p>We conducted a comprehensive analysis of CD8 T-cell responses to SARS-CoV-2 inactivated vaccines, focusing on HLA-A2-restricted epitopes derived from the Omicron variant. …”
  10. 10310

    Image 2_Characterizing HLA-A2-restricted CD8+ T-cell epitopes and immune responses to Omicron variants in SARS-CoV-2-inactivated vaccine recipients.tif by Chanchan Xiao (9522614)

    Published 2025
    “…</p>Methods<p>We conducted a comprehensive analysis of CD8 T-cell responses to SARS-CoV-2 inactivated vaccines, focusing on HLA-A2-restricted epitopes derived from the Omicron variant. …”
  11. 10311

    Image 1_Characterizing HLA-A2-restricted CD8+ T-cell epitopes and immune responses to Omicron variants in SARS-CoV-2-inactivated vaccine recipients.tif by Chanchan Xiao (9522614)

    Published 2025
    “…</p>Methods<p>We conducted a comprehensive analysis of CD8 T-cell responses to SARS-CoV-2 inactivated vaccines, focusing on HLA-A2-restricted epitopes derived from the Omicron variant. …”
  12. 10312

    Table1_CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.DOCX by Cataldo Martucci (3117069)

    Published 2024
    “…In mice exposed to tobacco smoke (TS), CHF6297, administered intranasally (i.n.) for 4 days at 0.03 or 0.3 mg/kg, dose-dependently inhibited the corticosteroid-resistant TS-induced neutrophil influx in the BALF. In a murine house dust mite (HDM) model of asthma exacerbated by influenza virus A (IAV) (H3N3), CHF6297 (0.1 mg/kg, i.n.) significantly decreased airway neutrophilia compared to vehicle-treated IAV/HDM-challenged mice. …”
  13. 10313

    Supplementary file 1_Comparative efficacy of femoral neck system vs. cannulated compression screws in young patients with femoral neck fractures: a systematic review and meta-analy... by Weishuai Zhang (22399933)

    Published 2025
    “…Meta-analysis revealed that, compared to CCS, FNS was associated with a significantly shorted fracture healing time (SMD = 16.30, 95% CI: 3.79–28.82, P < 0.001), decreased intraoperative fluoroscopy usage (WMD) = −8.14, 95% CI: −9.82 to −6.46, P < 0.001), and higher Harris hip scores at the final follow-up (WMD = −3.43, 95% CI: −4.08 to −2.77, P < 0.001). …”
  14. 10314

    Table_1_Association between serum iron levels and atherosclerotic cardiovascular diseases among American older adults: a cross-sectional study based on the National Health and Nutr... by Xiaochen Yu (3796927)

    Published 2024
    “…For serum iron levels below 131 μg/dL, each 10 μg/dL increase was associated with a 4% decrease in the odds of ASCVD (OR = 0.96; 95% CI, 0.93–0.98, p < 0.001). …”
  15. 10315

    Table1_Trends of antiseizure medication utilization among pregnant people in four Canadian provinces from 1998 to 2023; a study from the Canadian mother-child cohort active surveil... by Payam Peymani (12433284)

    Published 2024
    “…ASM utilization by drug class showcased significant shifts, with second-generation ASMs experiencing a notable rise. …”
  16. 10316

    Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study... by Xinyuan Mo (15468948)

    Published 2025
    “…All three hepatitis B vaccine regimens demonstrated comparable declines in anti-HBs levels, with a rapid decrease observed within 1-year of follow-up.…”
  17. 10317
  18. 10318

    Supplementary file 1_Full-dose versus reduced-dose comparison of direct oral anticoagulants for extended treatment of venous thromboembolism: a systematic review and meta-analysis... by Renshu Zhang (22775495)

    Published 2025
    “…</p>Conclusion<p>Reduced-dose DOACs were associated with a significant decrease in the risk of major bleeding/CRNMB compared with full-dose DOACs, but were not associated with a significant increase in the risk of recurrent VTE. …”
  19. 10319

    Data Sheet 1_Assessment of heat-killed E. coli expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and E. coli.docx by Surajit Patra (18400578)

    Published 2025
    “…The CHIKV neutralization assay results showed a two-fold decrease in CHIKV TCID50 value after 12 hours and a three-fold reduction after 120 hours. …”
  20. 10320

    Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic... by Hsiang-Ying Wu (22212274)

    Published 2025
    “…</p> <p>Eleven clinical trials published between 2015 and 2022 were included in our meta-analysis, with a total of 5572 eligible patients. This meta-analysis found that HR(+)/HER2(−) metastatic breast cancer treated with CDK4/6 inhibitors plus endocrine therapy can significantly improve progression-free survival(PFS) (HR: 0.55; <i>p</i> < 0.001), overall survival (OS) (HR: 0.79; <i>p</i> < 0.001), objective response rate (RR = 1.50; <i>p</i> < 0.001), clinical benefit rate (RR = 1.18; <i>p</i> < 0.001) and decrease progressive disease rate (RR = 0.49; <i>p</i> < 0.001). …”